Expressing support for the designation of September 30, 2025, as "Rare Cancer Day" to highlight the challenges patients with rare cancers face and to raise awareness and support efforts to improve early diagnosis and treatment.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill creates supports designating a Rare Cancer Day, recognizes challenges in detecting rare cancers, encourages partnerships for early diagnosis and treatment development, and supports funding for rare cancer research. The main policy areas are Healthcare and Government.
Who Benefits and How
Rare cancer patients would be affected, Medical research institutions would be affected, and Pharmaceutical companies would be affected.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Creates supports designating a Rare Cancer Day, recognizes challenges in detecting rare cancers, encourages partnerships for early diagnosis and treatment development, and supports funding for rare cancer research.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates supports designating a Rare Cancer Day, recognizes challenges in detecting rare cancers, encourages partnerships for early diagnosis and treatment development, and supports funding for rare cancer research.
Key Policy Areas
Healthcare, Government
Primary Purpose
The bill creates supports designating a Rare Cancer Day, recognizes challenges in detecting rare cancers, encourages partnerships for early diagnosis and treatment development, and supports funding for rare cancer research.
Policy Domains
Whole bill
Identified Gains
- Rare cancer patients
- Medical research institutions
- Pharmaceutical companies
Sponsors
Legislative Progress
In CommitteeMr. Kelly of Pennsylvania (for himself, Ms. Wasserman Schultz, Mr. …
Referred to the House Committee on Energy and Commerce.
Submitted in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Medical research institutions, Pharmaceutical companies
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology